| P50 | author | Rosa Fernandes | Q47503161 |
| | Frederico Teixeira | Q57903181 |
| | Jorge Oliveira | Q59675095 |
| | Edite Teixeira De Lemos | Q64190488 |
| | Flávio Reis | Q38545312 |
| | Helena Vala | Q47352510 |
| P2093 | author name string | Cristina Mega | |
| | Edite Teixeira de Lemos | |
| | Filipa Mascarenhas-Melo | |
| P2860 | cites work | Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 | Q27860575 |
| | Use and abuse of HOMA modeling | Q28263292 |
| | Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study | Q30320781 |
| | Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. | Q33215328 |
| | Progression of diabetic nephropathy. Insights from cell culture studies and animal models | Q33648914 |
| | Rodent models of nephropathy associated with type II diabetes. | Q33707059 |
| | Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat) | Q34003019 |
| | Obesity-related glomerulopathy: an emerging epidemic | Q34190647 |
| | Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice. | Q51382768 |
| | Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. | Q51497444 |
| | Trends in incidence of end-stage renal disease in Japan, 1983-2000: age-adjusted and age-specific rates by gender and cause. | Q54655646 |
| | Pathologic classification of diabetic nephropathy. | Q55052603 |
| | Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes | Q71534418 |
| | Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats | Q72324013 |
| | Studies of renal injury III: lipid-induced nephropathy in type II diabetes | Q73322118 |
| | Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats | Q73430341 |
| | Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker rat | Q74082999 |
| | The prevalence and management of cardiorenal risk factors in patients with diabetic nephropathy | Q79196433 |
| | Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs | Q79551083 |
| | Trends in incidence of treated end-stage renal disease, overall and by primary renal disease, in persons aged 20-64 years in Europe, Canada and the Asia-Pacific region, 1998-2002 | Q81095258 |
| | Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level | Q83572227 |
| | Pathological influence of obesity on renal structural changes in chronic kidney disease | Q84077100 |
| | Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes | Q84782119 |
| | Incretins: Clinical Perspectives, Relevance, and Applications for the Primary Care Physician in the Treatment of Patients With Type 2 Diabetes Mellitus | Q34374350 |
| | The biology of incretin hormones | Q34499706 |
| | Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fatty rats | Q35161497 |
| | Lipids and diabetic nephropathy | Q36659493 |
| | Relation of low glomerular filtration rate to metabolic disorders in individuals without diabetes and with normoalbuminuria | Q36662078 |
| | Incretins and their role in the management of diabetes | Q36973100 |
| | Pathophysiology of diabetic nephropathy | Q37059936 |
| | Type 2 diabetes and oral antihyperglycemic drugs | Q37066136 |
| | Diabetes and chronic kidney disease: a complex combination | Q37139159 |
| | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 |
| | Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes | Q37221770 |
| | The incretin system and its role in type 2 diabetes mellitus | Q37266863 |
| | Recent advances in the management of type 2 diabetes mellitus: a review. | Q37328847 |
| | The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions | Q37335669 |
| | Pathogenic perspectives for the role of inflammation in diabetic nephropathy. | Q37387708 |
| | Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism | Q37520505 |
| | Vascular disease in the metabolic syndrome: do we need to target the microcirculation to treat large vessel disease? | Q37538324 |
| | Sitagliptin: a review of its use in the management of type 2 diabetes mellitus | Q37703202 |
| | Oxidative stress in early diabetic nephropathy: fueling the fire | Q37820092 |
| | Diabetic nephropathy in 2010: Alleviating the burden of diabetic nephropathy | Q37833489 |
| | Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats | Q40756554 |
| | Role of the renin angiotensin system in diabetic nephropathy | Q42723231 |
| | A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin) | Q43046185 |
| | Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent. | Q43262211 |
| | Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats | Q43644419 |
| | Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats | Q43972544 |
| | Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis | Q44103908 |
| | Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. | Q45000524 |
| | Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen | Q45038702 |
| | Diabetes, the kidney, and cardiovascular risk. Foreword. | Q45959800 |
| | The factors for progression of the diabetic nephropathy: management and evolution | Q46095840 |
| | Angiotensin blockade and matrix synthesis by glomerular epithelial cells in high glucose: a further experimental insight into the pathophysiology of diabetic nephropathy. | Q46506887 |
| | Increased glomerular and extracellular malondialdehyde levels in patients and rats with diabetic nephropathy | Q46728417 |
| | A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. | Q46774459 |
| | Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule. | Q46852265 |
| | Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats | Q46975284 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | diabetic nephropathy | Q1129105 |
| | type 2 diabetes | Q3025883 |
| P304 | page(s) | 162092 | |
| P577 | publication date | 2011-11-30 | |
| P1433 | published in | Experimental Diabetes Research | Q26842719 |
| P1476 | title | Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat) | |
| P478 | volume | 2011 | |